High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin-ezetimibe combination therapy is capable of achieving near-normal lipid profles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD beneft, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin-ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confrmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the Efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.
|Number of pages||15|
|Journal||Vascular Health and Risk Management|
|Publication status||Published - 2010|
- Combination therapy
- Familial hypercholesterolemia
- Low-density lipoprotein cholesterol